At Telara Pharma, we develop innovative therapies based on cilastatin, a drug with a solid safety record and a powerful neuroprotective effect on the retina. Our goal is to transform glaucoma and diabetic retinopathy retreatments through a strategy that targets retinal neurodegeneration and inflammation—two key processes that current medicine does not address. Unlike therapies focused solely on reducing intraocular pressure (IOP), our ophthalmic drops directly protect retinal ganglion cells, preserving vision and quality of life.
| Website | https://www.telarapharmahealth.com/ |
| Employees | 8 (1 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology Research |
| Keywords | Drug Repurposing, Pharmaceutical, Drug Development, Inflammatory Disorders, Glaucoma Treatment, Biopharmaceutical, New Therapies, Nephrology, Clinical Trials, Ophthalmology, Therapeutics, Biotechnology, Pharma, Research, Healthcare, Medicine |
Looking for a particular Telara Pharma employee's phone or email?
Teresa Tarragó is the CEO at Telara Pharma of Telara Pharma.
1 people are employed at Telara Pharma.